The news that a new treatment has been approved by NICE for use in the NHS will bring hope to thousands of women living with advanced cervical cancer. The decision, which follows an exhaustive review of clinical trial data, paves the way for the introduction of pembrolizumab (Keytruda) – a revolutionary immunotherapy drug that has shown remarkable promise in extending survival times and improving quality of life.
According to NICE guidelines, pembrolizumab will be prescribed in combination with chemotherapy, with or without bevacizumab, for adults whose cervical cancer has either recurred or spread to other parts of the body. Crucially, this new treatment is reserved for those who have not previously received chemotherapy for their advanced disease.
Each year, approximately 3,200 women in the UK are diagnosed with cervical cancer – a condition that disproportionately affects women under the age of 50. While the NHS's cervical screening programme has proven to be highly effective in detecting pre-cancerous changes at an early stage, some women still develop advanced or recurrent disease. The approval of pembrolizumab marks a significant step forward in providing more effective interventions for this patient group.
Pembrolizumab works by harnessing the power of the body's immune system to fight cancer cells, offering a fresh hope for those with hard-to-treat cancers. Its combination with chemotherapy is designed to enhance the efficacy of treatment by simultaneously boosting the patient's immune response against the tumour.
As part of this new guidance, NHS England will work to ensure that eligible patients have access to pembrolizumab as soon as possible. This involves updating clinical pathways and training healthcare professionals in its administration, ensuring that those who need it most can benefit from this innovative treatment.
If you're concerned about cervical cancer or your eligibility for screening, we recommend speaking with your GP or contacting NHS 111 for medical advice. The NHS website also provides valuable information on cervical cancer symptoms and screening.